PLUS THERAPEUTICS, INC.
4200 Marathon Blvd.
Suite 200
Austin, TX 78756
August 15, 2022
VIA EDGAR
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
| Re: | Plus Therapeutics, Inc. |
Registration Statement on Form S-1 (File No. 333-266684)
Request for Acceleration of Effective Date
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Plus Therapeutics, Inc., a Delaware corporation, hereby requests that the Securities and Exchange Commission accelerate the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-266684) and declare the Registration Statement effective as of Wednesday, August 17, 2022, at 4:00 p.m., Eastern Daylight Time, or as soon as practicable thereafter.
Please contact William I. Intner of Hogan Lovells US LLP at (410) 659-2778 with any questions. Also, please notify Mr. Intner when this request for acceleration has been granted.
| Very truly yours, | ||
| PLUS THERAPEUTICS, INC. | ||
| By: | /s/ Andrew Sims | |
| Name: Andrew Sims | ||
| Title: Chief Financial Officer | ||
| cc: | William I. Intner, Hogan Lovells US LLP |